RALEIGH, N.C., Oct. 6 /PRNewswire/ -- Pioneer Surgical Technology, Inc., a global medical device provider in orthopaedics, spine, and biologics, is proud to announce the United States Patent Office has reissued a patent further strengthening Pioneer’s market position in nanocrystalline derived products used in orthopaedics.
The patent supports Pioneer Surgical’s nanocrystalline calcium phosphate technology nanOss. Mr. Shane Ray, General Manager- Biologics stated, “This patent issuance is a great achievement with our license with Massachusetts Institute of Technology (M.I.T.) and Pioneer’s biologic research and development team. Throughout recent history medical device and biologic companies have attempted to create synthetic bone. With the advances from Pioneer’s team and through the addition of the first FDA cleared product utilizing nanocrystalline materials in orthopaedics, we feel we have created the closest technology to human bone available to patients today.”
Pioneer’s first developed biologic product, nanOss Bioactive was launched in the United States in 2009 and is a bone void filler/bone graft substitute used in orthopaedics.
For more information regarding nanOss Bioactive, please visit the Pioneer Surgical website at www.pioneersurgical.com.
About Pioneer Surgical Technology, Inc.
Pioneer® Surgical Technology, Inc. is a dynamic medical device firm founded in 1992. Pioneer’s focus on innovation has resulted in over 120 U.S. and foreign patents, with numerous patents pending. The company has a comprehensive portfolio of orthopaedic, spine and biologic systems. Pioneer entered the orthobiologics market with two acquisitions in 2007. Our Orthopaedic, Spine, and Biologics divisions produce state of the art, cost-effective solutions for surgical procedures that have proven difficult or problematic for both surgeons and patients. Pioneer employs more than 270 people worldwide. For more information on Pioneer and its products, visit www.pioneersurgical.com.
SOURCE Pioneer Surgical Technology, Inc.
